vs
Side-by-side financial comparison of Kearny Financial Corp. (KRNY) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $44.3M, roughly 1.7× Kearny Financial Corp.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 14.8%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 9.3%).
Kearny Financial Corp. is a U.S.-based bank holding company operating Kearny Bank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, mortgages, business loans, and wealth management services, primarily serving customers across New Jersey and the New York metropolitan region.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
KRNY vs PBYI — Head-to-Head
Income Statement — Q1 FY2027 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.3M | $75.5M |
| Net Profit | $10.1M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 22.9% | — |
| Revenue YoY | 14.8% | 27.7% |
| Net Profit YoY | 7.3% | — |
| EPS (diluted) | $0.16 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 27 | $44.3M | — | ||
| Q1 26 | $44.3M | — | ||
| Q4 25 | $43.5M | $75.5M | ||
| Q3 25 | $43.6M | $54.5M | ||
| Q2 25 | $40.8M | $52.4M | ||
| Q1 25 | $38.6M | $46.0M | ||
| Q4 24 | $37.5M | $59.1M | ||
| Q3 24 | $37.1M | $80.5M |
| Q1 27 | $10.1M | — | ||
| Q1 26 | $10.1M | — | ||
| Q4 25 | $9.4M | — | ||
| Q3 25 | $9.5M | $8.8M | ||
| Q2 25 | $6.8M | $5.9M | ||
| Q1 25 | $6.6M | $3.0M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $6.1M | $20.3M |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 27.1% | 22.7% | ||
| Q3 25 | 27.5% | 17.6% | ||
| Q2 25 | 20.0% | 12.7% | ||
| Q1 25 | 20.3% | 8.7% | ||
| Q4 24 | 20.9% | 22.6% | ||
| Q3 24 | 19.4% | 27.4% |
| Q1 27 | 22.9% | — | ||
| Q1 26 | 22.9% | — | ||
| Q4 25 | 21.7% | — | ||
| Q3 25 | 21.8% | 16.2% | ||
| Q2 25 | 16.6% | 11.2% | ||
| Q1 25 | 17.2% | 6.5% | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 16.4% | 25.2% |
| Q1 27 | $0.16 | — | ||
| Q1 26 | $0.16 | — | ||
| Q4 25 | $0.15 | $0.26 | ||
| Q3 25 | $0.15 | $0.17 | ||
| Q2 25 | $0.11 | $0.12 | ||
| Q1 25 | $0.11 | $0.06 | ||
| Q4 24 | $0.10 | $0.40 | ||
| Q3 24 | $0.10 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $123.8M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $763.0M | $130.3M |
| Total Assets | $7.6B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 27 | $123.8M | — | ||
| Q1 26 | $123.8M | — | ||
| Q4 25 | $147.3M | $97.5M | ||
| Q3 25 | $130.1M | $94.4M | ||
| Q2 25 | $167.3M | $96.0M | ||
| Q1 25 | $126.1M | $93.2M | ||
| Q4 24 | $141.6M | $101.0M | ||
| Q3 24 | $155.6M | $96.7M |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M |
| Q1 27 | $763.0M | — | ||
| Q1 26 | $763.0M | — | ||
| Q4 25 | $757.4M | $130.3M | ||
| Q3 25 | $753.2M | $115.3M | ||
| Q2 25 | $746.0M | $104.7M | ||
| Q1 25 | $748.1M | $97.1M | ||
| Q4 24 | $744.9M | $92.1M | ||
| Q3 24 | $751.5M | $71.1M |
| Q1 27 | $7.6B | — | ||
| Q1 26 | $7.6B | — | ||
| Q4 25 | $7.6B | $216.3M | ||
| Q3 25 | $7.6B | $202.9M | ||
| Q2 25 | $7.7B | $194.9M | ||
| Q1 25 | $7.7B | $196.2M | ||
| Q4 24 | $7.7B | $213.3M | ||
| Q3 24 | $7.8B | $220.7M |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $14.3M | $14.4M | ||
| Q3 25 | $1.5M | $9.7M | ||
| Q2 25 | $24.8M | $14.1M | ||
| Q1 25 | $16.8M | $3.6M | ||
| Q4 24 | $-2.7M | $15.6M | ||
| Q3 24 | $2.5M | $11.0M |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | $21.4M | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | 52.4% | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 8.3% | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% |
| Q1 27 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.51× | — | ||
| Q3 25 | 0.16× | 1.10× | ||
| Q2 25 | 3.66× | 2.41× | ||
| Q1 25 | 2.53× | 1.21× | ||
| Q4 24 | -0.40× | — | ||
| Q3 24 | 0.42× | 0.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
